Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder

The pathophysiology of major depressive disorder (MDD) is thought to result from impaired connectivity between key brain networks. Gamma-aminobutyric acid (GABA) is the key inhibitory neurotransmitter in the brain, working primarily via GABA(A) receptors, with an important role in virtually all physiologic functions in the brain. Some neuroactive steroids (NASs) are positive allosteric modulators (PAMs) of GABA(A) receptors and potentiate phasic and tonic inhibitory responses via activation of synaptic and extrasynaptic GABA(A) receptors, respectively. This review first discusses preclinical and clinical data that support the association of depression with diverse defects in the GABAergic system of neurotransmission. Decreased levels of GABA and NASs have been observed in adults with depression compared with healthy controls, while treatment with antidepressants normalized the altered levels of GABA and NASs. Second, as there has been intense interest in treatment approaches for depression that target dysregulated GABAergic neurotransmission, we discuss NASs approved or currently in clinical development for the treatment of depression. Brexanolone, an intravenous NAS and a GABA(A) receptor PAM, is approved by the U.S. Food and Drug Administration for the treatment of postpartum depression (PPD) in patients 15 years and older. Other NASs include zuranolone, an investigational oral GABA(A) receptor PAM, and PH10, which acts on nasal chemosensory receptors; clinical data to date have shown improvement in depressive symptoms with these investigational NASs in adults with MDD or PPD. Finally, the review discusses how NAS GABA(A) receptor PAMs may potentially address the unmet need for novel and effective treatments with rapid and sustained antidepressant effects in patients with MDD.

Automated summary

The pathophysiology of major depressive disorder is associated with impaired connectivity in key brain networks, which involves the GABAergic system of neurotransmission. Defects in GABA and neuroactive steroids (NASs) have been observed in adults with depression, and treatment with antidepressants can normalize these levels. There is interest in using NAS GABA(A) receptor positive allosteric modulators (PAMs) as potential treatments for depression, with brexanolone, zuranolone, and PH10 showing promise in clinical development. These NASs may provide novel and effective treatments for patients with major depressive disorder.